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Background: Both dehydroepiandrosterone (DHEAS) and cortisol are secreted by the
adrenal glands and may modulate metabolic syndrome (MetS), which often affects the health
of patients with schizophrenia. The relationship between the serum levels of these hormones
and MetS has not been established.
Purpose: In this pilot study, we investigated the serum levels in schizophrenia patients with
and without MetS and compared them with those in healthy volunteers.
Patients and Methods: After obtaining informed consent, 110 patients with acute paranoid
schizophrenia were recruited directly after admission to the Mental Health Research Institute.
The control group consisted of 51 persons reported on questioning to be mentally and
somatically healthy. Blood samples to prepare serum were drawn after an 8-h overnight
fast during one of the first days of admission. Serum cortisol and DHEAS concentrations
were quantified by enzyme-linked immunosorbent assay.
Results: A total of 42 patients had MetS and 68 patients were without MetS. The cortisol blood
level was significantly (p = 0.012) higher in schizophrenia patients without MetS in comparison
to healthy controls, while patients with schizophrenia and a MetS have significantly (p = 0.014)
lower DHEAS levels than healthy volunteers. These differences could, however, exclusively be
attributed to female participants. Analysis of covariance adjusted for gender and age demon-
strated a significant relationship between age and DHEAS levels (F = 9.512, р = 0.003).
Conclusion: Lower DHEAS serum levels in relationship to MetS become evident in
women, but not in men, and have age differences as a confounding factor.
Keywords: schizophrenia, metabolic syndrome, acute relapse, cortisol, dehydroepiandrosterone,
female
Introduction
Schizophrenia is a major severe mental illness (SMI) with a median lifetime
prevalence of 6.35 per 1000 persons (25% quartile: 4.10; 75% quartile: 8.72).1
The disease is associated with loss of life expectancy of on average 14.5 (95% CI
11.2–17.8) years.2 This is to an important extent caused by cardiovascular disease,
which is associated with schizophrenia with a relative risk of 1.53 (CI95% 1.27–-
1.86) in comparison to the incidence in a reference group.3 A major contributor to
this increased cardiovascular disease burden may be the higher prevalence of
metabolic syndrome (MetS), which amounted to an overall rate of 32.5% (95%
CI 30.1–35.0%) in patients with schizophrenia.4 In the general population,
a diagnosis of MetS has a relative risk of twofold for cardiovascular disease over
5–10 years and at least a fivefold risk for type 2 diabetes.5 MetS is characterized by
abdominal obesity, hyperglycaemia, dyslipidaemia and hypertension.5 MetS has
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been associated with the usage of clozapine and second-
generation antipsychotics,4,6-8 but certain components are
also more prevalent in drug-naïve patients with
schizophrenia.4 Over 20% of the treatment-naïve schizo-
phrenia patients and first-episode patients were shown to
have a lowered HDL-cholesterol level and a glucose dys-
regulation/insulin resistance.9,10 It has been suggested that
the effects of inflammatory mediators causally contribute
to the pathology of schizophrenia and diabetes that accom-
panies the disorder.11,12 Several studies had delivered evi-
dence for specific cytokine alterations in different stages of
schizophrenia.13 In a previous paper, we have suggested
that certain apolipoproteins (Apos), more specifically
ApoA1, may play a role in the pathogenesis of
schizophrenia.14 ApoA1 and ApoE are also known to
have both pro- and anti-inflammatory effects depending
on particular circumstances.15–17 The same is true for
glucocorticoids,18 which modulate gene expression by
binding to a member of the nuclear receptor family,
which affects the expression of pro- and anti-
inflammatory modulators by immune cells,18–20 next to
a variety of other cellular effects.19 Apart from anti-
inflammatory activity glucocorticoids also have profound
effects on metabolism, which include causing central obe-
sity, hepatic steatosis, insulin resistance, glucose intoler-
ance and dyslipidaemia.21,22 Due to their influence on
liver, skeletal muscle and adipose tissue as well as on
pancreatic alpha and beta cells, chronic exposure to
increased levels of circulating cortisol may hence contri-
bute to acquiring MetS via another mechanism than mod-
ulating inflammation.22 In a meta-analysis of the basal
serum cortisol levels of 2953 persons with MetS and
8855 without MetS no significant differences were
observed.23 This is not necessarily the same in persons
with schizophrenia. In spite of substantial heterogeneity,
a meta-analysis of 44 studies showed a small-to-medium
increase in morning cortisol levels in patients with schizo-
phrenia (N=1520) compared to controls (N = 1093).24 The
same was true for 959 individuals with first-episode psy-
chosis in comparison to 1121 controls included in 27
studies.25 Blood cortisol levels were significantly
increased in individuals with first-episode psychosis com-
pared to controls with a small-to-medium effect size
and significant heterogeneity between the results of the
meta-analysed studies. Fasting plasma cortisol was not
associated with obesity measures including BMI, waist
circumference and visceral fat in 81 subjects with early
psychosis.26
Dehydroepiandrosterone (DHEA) and its sulfate ester
(DHEAS) also regulate the production of pro-inflammatory
cytokines,27 next to a wide variety of other effects.27–29
DHEA(S) is converted into androgens and/or estrogens28
and it exerts anti-glucocorticoid activity in adipose tissue29,30
and brain.27 Both cross-sectional and longitudinal studies have
shown that the levels of testosterone may modulate the risk of
MetS and diabetes.31 However, DHEA(S) regulates adipose
tissue metabolism (also) via another mechanism than
testosterone.32,33 In contrast to testosterone, non-fasting
DHEAS serum levels were not related to incident MetS in
a prospective cohort of 1004 male adults during a median
follow-up time of 5.0 years.34 The cortisol/DHEAS ratio has
been found to be more associated with MetS in 4255 male
Vietnam veterans35 and to better predict survival in a group of
313 aged (>70 years old) persons of both genders during an
8-year follow-up.36 In the only study of fasting cortisol/
DHEAS ratio in patients with euthymic bipolar disorder (N
= 60) or schizophrenia (N = 62), no significant associations of
baseline cortisol levels, DHEAS levels and the cortisol/
DHEAS ratio with the presence of MetS (n= 43) were
found.37 These authors not differentiated between men and
women.
The aim of the current pilot study is to determine the
possible association between levels of cortisol, DHEAS,
their ratio and the presence of MetS in patients with
schizophrenia. We hypothesized that cortisol might
decrease and DHEAS increases the prevalence of MetS.
Patients and Methods
Patients
This study was carried out in accordance with the Code of
Ethics of the World Medical Association (Declaration of
Helsinki 1975, revised in Fortaleza, Brazil, 2013), established
for experiments involving humans. We recruited newly
admitted patients from the Mental Health Research Institute
Inpatient Department, clinics of Siberian State Medical
University and Psychiatric Hospital located in Tomsk,
Tomsk oblast (region) of Siberia, Russia. Recruitment started
after the study was approved (protocol N187, 24.04.2018) by
the Local Bioethics Committee of theMental Health Research
Institute. Each patient provided written informed consent after
a proper explanation was given. The inclusion criteria, criteria
for MetS and clinical assessments are described in a previous
paper.14 We included 110 patients with the diagnosis of para-
noid schizophrenia verified according to the International
Statistical Classification of Diseases, 10th Revision (ICD-10:
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F20) and who were suffering from an acute relapse. Patients
have been divided into groups according to criteria of the
International Diabetes Federation (IDF, 2005): 42 patients
withMetS and 68 patients withoutMetS. All patients received
antipsychotic treatment but may have been incompliant in the
previous period.
Control Group
The control group consisted of 51 persons who were
recruited from a group of blood donors, hospital staff
members, and students, on a voluntary basis. They
reported on questioning to be mentally and somatically
healthy individuals.
Blood Sampling
Laboratory examination was conducted during the first
days of hospitalization. Blood samples were drawn after
an 8-h overnight fast into tubes with a clot activator
(SiO2) to isolate the serum (BD Vacutainer). Blood sam-
ples with SiO2 were centrifuged for 30 min at 2000×g at
4°C to isolate the serum; the serum was stored at −20°C
(or – 80°C) until analysis.
Chemical Analysis
Reagent kits designed to quantify serum cortisol and
DHEAS concentrations by enzyme-linked immunosorbent
assay (ELISA) were used. The reaction was carried out in
accordance with the instructions attached to the kits with
the mandatory control of standard serum included in the
test system. ELISA results were evaluated on an automatic
microplate spectrophotometer at a wavelength of 450 nm.
The final results were expressed in units recommended by
manufacturers for constructing calibration plots (cortisol in
nmol/L, DHEA-S in μg/mL). The units of DHEAS in μg/
mL were converted to nmol/L to calculate the Cortisol/
DHEAS ratio. According to the instructions for the ELISA
kit, the concentration of the neurosteroid (in μg/mL) must
be multiplied by a factor of 2700.
Statistics
Statistical analyses were performed using the SPSS soft-
ware for Windows, version 20.0. The data were tested for
the normality of the distribution by the Shapiro–Wilk test.
Between two-group differences were evaluated using the
Mann–Whitney U-test for independent samples with non-
normal distribution and Student’s t-test for samples with
normal distribution. Between three-group differences were
evaluated using the analysis of variance (ANOVA). Also,
a three-group and two-group comparison were carried out
by an analysis of covariance (ANCOVA) with gender and
age as a covariate. Results were expressed as median with
25%- and 75%-quartiles (Me [Q1; Q3]) and mean with
standard deviation (M±SD). P-values less than 0.05 were
considered as significant.
Results
Forty-two patients met IDF-criteria for MetS. The charac-
teristics of the patients are specified in Table 1. There were
no group differences in gender and clinical (leading symp-
toms, duration of illness) parameters except for age
(patients with MetS were statistically older). Fifty-one
healthy individuals (M/F = 13/38) were recruited to serve
as controls.
Table 1 Socio-Demographic Characteristics of Patients with Schizophrenia and Healthy Individuals
Patients without MetS (n=68) Patients with MetS (n=42) Healthy Persons (n=51) p-value
Age, years (M±SD) 33.93±8.77 42.42±11.17 33.21±9.112 <0.001*
Male
Quantity, % (n) 44.9% (31) 54.8% (23) 25.2% (13)
Age, years (M±SD) 31.68±7.071 37.15±10.456 30.56±9.948 0.024*
Female
Quantity, % (n) 55.1% (37) 45.2% (19) 74.5% (38)
Age, years (M±SD) 35.51±9.009 47.16±10.777 32.68±8.388 <0.001*
Age of manifestation, years (M±SD) 23.08±6.271 24.65±6.765 - 0.07
Duration of illness, years (M±SD) 12.41±14.559 17.43±9.363 - <0.001*
PANSS scale, total score (M±SD) 94.73±17.478 98.15±15.236 - 0.381
Notes: Comparisons between groups were performed using ANOVA (3 groups) and t-test (2 groups). *p<0.05 – statistically significant difference.
Abbreviations: MetS, metabolic syndrome; M, mean; SD, standard deviation; PANSS, Positive and Negative Syndrome Scale.
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The serum cortisol level was significantly (p = 0.012)
higher in schizophrenia patients without MetS in compar-
ison to healthy controls, while patients with schizophrenia
and a MetS had significantly (p = 0.014) lower DHEAS
levels than healthy volunteers (Table 2). Other differences
were not significant.
However, female gender turns out to be of major impor-
tance. In men neither multiple (Table 3) nor pairwise (data
not shown) comparisons between healthy volunteers, schi-
zophrenia patients without MetS and patients with MetS
resulted in any significant differences. However, in women
multiple comparison resulted in trends or a significant dif-
ference. This was mainly attributable to the relatively high
cortisol levels in women without MetS in comparison to
healthy controls (pairwise comparison: p = 0.003) and the
relative low DHEAS levels of patients with MetS in com-
parison to healthy controls and patients without MetS (pair-
wise comparisons: p = 0.001 resp. 0.017).
A three-group ANCOVA with gender and age as
a covariate showed that significantly increased cortisol levels
remained in the studied groups (F = 3.220, р = 0.045), but we
did not find differences in DHEAS levels (F = 0.331, р =
0.719) and cortisol/DHEAS ratio (F = 0.326, р = 0.723) any-
more (Supplementary Table 1). We found relations between
age and DHEAS levels (F = 19.341, р = 0.0001) as well as
between age and cortisol/DHEAS ratio (F = 5.973, р = 0.017).
When comparing groups of schizophrenia patients with-
out MetS and healthy controls with ANCOVA adjusted for
gender and age, significantly increased cortisol levels
remained (F = 7.023, р = 0.010), but also we found relations
between cortisol levels and gender (F = 5.617, р = 0.021).
Comparing groups of schizophrenia patients with MetS
and healthy controls with ANCOVA including gender and
age as a covariate, we found relations between age and
DHEAS levels (F = 9.512, р = 0.003).
Comparison of the relationships between DHEAS, cor-
tisol and the severity of metabolic syndrome as well as
psychotic symptoms led to no significant differences (see
Supplementary Tables 2 and 3). However, due to the many
uncertainties about the reasons for possible relationships,
our main conclusions were not affected.
Discussion
The main objective of this pilot study, which was an
intermediate step of studying the role of inflammation in
causing MetS, was the partial verification of the findings
of Vuksan-Ćusa et al, who measured cortisol and DHEAS
in a combined group of 60 patients with bipolar disorder
and 62 patients with schizophrenia.37 We limited our study
population to 110 patients with a diagnosis of paranoid
schizophrenia and also studied 51 healthy volunteers as
a reference group. Our most important finding is that the
relationship of particularly DHEAS and MetS differs
between the two genders. In men, only small difference
was observed between healthy volunteers and patients
with or without MetS. In women, however, cortisol levels
Table 2 The Concentration of Cortisol and DHEAS in the Blood Serum of Healthy Individuals and Patients with
Schizophrenia with Metabolic Syndrome and Without It (M±SD)
Healthy Persons Patients without MetS Patients with MetS p-value












Notes: Comparisons between groups were performed using ANOVA and t-test. *p<0.05 – statistically significant difference.
Abbreviations: MetS, metabolic syndrome; M, mean; SD, standard deviation; DHEAS, dehydroepiandrosterone sulfate; P1–2, statistical significance
of differences when comparing healthy individuals and patients without MetS; P1–3, statistical significance of differences when comparing healthy
individuals and patients with MetS; P2–3, statistical significance of differences when comparing patients with and without MetS.
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tend to be higher in patients in comparison to healthy
individuals, but DHEAS levels are lower and particularly
so in patients with MetS. However, the latter relationship
is confounded by age differences. In their study, Vuksan-
Ćusa et al did not discriminate between men and women.
The interpretation of our results is not a simple matter. We
actually did not obtain support for a possible association
between cortisol levels and MetS. However, in women, but
hardly not in men, cortisol levels were found to be higher in
persons with schizophrenia. This partly corresponds to the
results of the published meta-analysis.24,25 However, a direct
comparison between male and female patients versus controls
was absent from these studies. Two-group ANCOVA adjusted
for gender and age still demonstrated increased cortisol levels
in schizophrenia patients without MetS and also the relation-
ship between cortisol levels and gender. In our population,
DHEAS levels were lowest in patients with MetS. In females,
a pairwise comparison with patients without MetS as well as
healthy volunteers resulted in a significant difference. DHEA
is known to have insulin-promoting effects by enhancing
insulin release and insulin receptor sensitivity.32,33 However,
non-fasting DHEAS serum levels were not related to incident
MetS in a prospective cohort of 1004 male adults during
a median follow-up time of 5.0 years.34 In a meta-analysis
of 13 studies, Misiak et al observed significantly higher levels
of DHEAS in a group of patients with schizophrenia com-
pared to controls in a pooled analysis of all studies.38
However, subgroup analysis revealed that no significant dif-
ferences were found in acutely relapsed (3 studies) and stable
(5 studies) multiple-episode patients. Our findings concerning
female patients with schizophrenia versus controls differ from
those of Bulut et al, who compared 32 pre-menopausal
Table 3 Cortisol and DHEAS Levels and Arbitrary Cortisol/DHEAS Ratio for Men and Women Separately
Healthy Persons Patients without MetS Patients with MetS p-value
Cortisol, nmol/L (M±SD)
Male








DHEAS, µg/mL (M [Q1;Q3])
Male


















Notes: Comparisons between groups were performed using ANOVA, t-test and Mann–Whitney U-test. *p<0.05 – statistically significant
difference.
Abbreviations: MetS, metabolic syndrome; M, mean/median; SD, standard deviation; Q1, lower quartile; Q3, upper quartile; DHEAS, dehydroe-
piandrosterone sulfate; P1–2, statistical significance of differences when comparing healthy individuals and patients without MetS; P1–3, statistical
significance of differences when comparing healthy individuals and patients with MetS; P2–3, statistical significance of differences when comparing
patients with and without MetS.
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women with stable schizophrenia and 32 age- and sex-
matched healthy controls.39 However, although several inves-
tigators report higher levels in female patients versus
controls,40 other researchers obtained contrasting results.41,42
The most important difference within the context of gender
aspects of DHEA-physiology is, of course, the high levels of
testosterone in males. In men, gonadal testosterone is most
important, while in women the major source of androgens is
DHEAS.43 DHEA(S) is converted into testosterone and estra-
diol, and in individuals with panhypopituitarism, whose
gonads do not produce sex hormones, a 50 mg dose of
DHEA resulted in DHEA plasma levels as observed in
young adults, in testosterone levels similar to those observed
in young women and estradiol levels were within the normal
range observed in men.44 The problem with DHEA is that
DHEA secretion peaks at age 25–30 yr and declines
thereafter.43,44 The results of ANCOVA adjusted for gender
and age demonstrated a confounding influence of age differ-
ence in our study. Age differences may contribute to the lower
DHEAS levels we found in female patients in comparison to
males, but we cannot be certain that this sufficiently explains
all differences. Aged-matched, longitudinal studies are prob-
ably necessary to investigate how the disease process, mensis,
menopause and pharmacological effects modify DHEAS pro-
duction during the course of time and to elucidate the back-
ground of this difference between female patients and control
subjects. Perhaps, higher testosterone levels in males prevent
that the effects of a DHEAS-related factor, whatever that may
be, become evident. A possibility might be that higher meta-
bolism of DHEAS in patients with MetS is inhibited by
testosterone. Therefore, parallel measurements of pituitary
(ACTH, FSH, prolactin), adrenal (cortisol, DHEAS), gonadal
(testosterone, estradiol, progesterone), and metabolic hor-
mones (insulin, ghrelin, leptin) of age-matched patients with
and without metabolic syndrome, in women in relationship to
the menstrual cycle and menopause, are indicated for the
future.
This pilot study has several limitations. We measured
only cortisol and DHEAS and the tested individuals were
not completely aged-matched with each other. Usually, it is
difficult while doing this type of research to find sufficiently
healthy persons of comparable age and sex to the studied
patient group. Many female patients with schizophrenia have
secondary amenorrhoea or (like most young women) use
contraceptive drugs. When a cohort of patients with schizo-
phrenia is divided into persons with or without MetS, the first
group has typically an older age. The findings of this study
are preliminary in a certain respect and need verification, but
it may be useful to distinguish male and female patients when
studying the mechanism of metabolic syndrome.
Conclusion
We measured cortisol and dehydroepiandrosterone sul-
phate (DHEAS) serum levels in 51 healthy individuals
and 110 patients with paranoid schizophrenia of which
42 had a metabolic syndrome (MetS) and 68 patients not.
Our results indicate that female gender turns out to be of
major importance. In men, no statistically significant dif-
ferences between the three groups were observed. In
women, relatively high cortisol levels were found in
women without MetS in comparison to healthy controls
and relatively low DHEAS levels in patients with MetS in
comparison to healthy controls and patients without MetS.
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